Hhlr Advisors, Ltd. I Mab Transaction History
Hhlr Advisors, Ltd.
- $2.61 Billion
- Q4 2024
A detailed history of Hhlr Advisors, Ltd. transactions in I Mab stock. As of the latest transaction made, Hhlr Advisors, Ltd. holds 5,980,568 shares of IMAB stock, worth $5.8 Million. This represents 0.19% of its overall portfolio holdings.
Number of Shares
5,980,568
Previous 6,909,220
13.44%
Holding current value
$5.8 Million
Previous $8.57 Million
40.67%
% of portfolio
0.19%
Previous 0.2%
Shares
6 transactions
Others Institutions Holding IMAB
# of Institutions
34Shares Held
16.5MCall Options Held
0Put Options Held
14.5K-
Decheng Capital Management Iii (Cayman), LLC4.17MShares$4.04 Million3.04% of portfolio
-
Morgan Stanley New York, NY3.54MShares$3.44 Million0.0% of portfolio
-
Sg Americas Securities, LLC476KShares$461,5860.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny431KShares$417,8760.0% of portfolio
-
Two Sigma Investments, LP New York, NY330KShares$320,2990.0% of portfolio
About I-Mab
- Ticker IMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,098,800
- Market Cap $80.6M
- Description
- I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...